Changes in the serum levels of autoantibody to nerve growth factor in patients with schizophrenia.

Abstract

Studies were performed on 54 patients with different types of schizophrenia-paranoid (8), recurrent-progressive (30), and slowly progressive (16), with ICD-10 rubrics F20.00 and F20.01, F20.22 and F20.02, and F21 respectively. An immunoenzyme method was used to demonstrate that schizophrenia patients had elevated levels of autoantibody to nerve growth factor, by a factor of 1.5 compared with a group of 70 healthy subjects. The autoantibody level was related to the stage of disease: during the active phase, there was a significant increase compared with patients in remission (1.38 +/- 0.26 and 0.92 +/- 0.25 U respectively). There were no differences between variants with different disease courses. The authors suggest that the data obtained here indicate that the autoantibody level can be used as a measure of the activity of the disease process.

• Authors: T P Klyushnik, E V Danilovskaya, O E Vatolkina, I L Turkova, Tsutsul'kovskaya MYa, V A Orlova, V G Kaleda
• Journal: Neuroscience and behavioral physiology (Neurosci Behav Physiol) 1999 May-Jun Vol. 29 Issue 3 Pg. 355-7 ISSN: 0097-0549 [Print] United States
• PMID: 10493550 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Autoantibodies
• Nerve Growth Factors

Topics

• Adult
• Autoantibodies (blood)
• Humans
• Middle Aged
• Nerve Growth Factors (immunology)
• Schizophrenia (blood, immunology)